Roche Holding AG (RHHBY)
| Market Cap | 352.29B +30.8% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 23.07 |
| Forward PE | 16.87 |
| Dividend | 0.97 (1.81%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 855,861 |
| Open | 54.43 |
| Previous Close | 55.22 |
| Day's Range | 54.43 - 55.20 |
| 52-Week Range | 39.50 - 60.85 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 59.66 (+8.54%) |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $59.66, which is an increase of 8.54% from the latest price.
News
A Prevention Prescription for Hong Kong
Roche Diagnostics Hong Kong general manager Ronald Lo is pushing the city beyond reactive medicine towards a prevention-led system powered by automation, AI and empowered patients. For Ronald Lo, diag...
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies
WATERTOWN, Mass.--(BUSINESS WIRE)--Treeline Biosciences, Inc. (“Treeline”) today announced a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-1...
Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion
Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst Emily Bodnar believes that remibrutinib will be favore...
Simcere Zaiming Enters Exclusive Global License Agreement With Roche For SIM0660
(RTTNews) - Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) announced it has entered into an exclusive global licensing agreement with Roche (RHHBY) for the development and com...
Roche signs global licensing pact for Simcere's experimental blood cancer drug
Switzerland's Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
Roche launches mangrove plantation drive along Nethravathi
Vana Charitable Trust team plants 3,000 saplings in a day as part of a three-phase river restoration project backed by CSR funding
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
A jury in Delaware federal court determined on Friday that Qiagen's Parse Biosciences must pay 10x Genomics' Scale Biosciences and Roche [RIC:RIC:ROGUS.UL] $4.8 million for violating their patent righ...
BioNTech Kills a Cancer Trial Roche Helped Build
BioNTech Kills a Cancer Trial Roche Helped Build
mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley
After BioNTech (BNTX) announced the discontinuation of its Phase 2 study partnered with Roche (RHHBY) of autogene cevumeran, an individualized mRNA immunotherapy, or cancer vaccine, in adjuvant colore...
Roche announces new two-year data from Phase IIIb/IV SALWEEN study
Roche (RHHBY) announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo, presented at the 19th Asia-Pacific Vitreo-retina Society Congress in Australia. The results showed significan...
DualityBio, Genentech Enter Global Deal To Develop Next-Gen ADCs
(RTTNews) - Duality Biotherapeutics, Inc. (9606.HK) on Friday announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group, to develop ne...
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
RHHBY Looks 39.2% Overvalued on GF Valueâ¢
RHHBY Looks 39.2% Overvalued on GF Valueâ¢
Roche receives FDA approval for companion diagnostic tests for Ziihera
Roche (RHHBY) announced that it has received FDA approval for expanded use of its PATHWAY HER2 and VENTANA HER2 Dual ISH DNA Probe Cocktail tests. “These companion diagnostics are now…
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma. Differential diagnosis...
The Zacks Analyst Blog Highlights Berkshire, Roche Holding, RTX, The Eastern and AmeriServ
Berkshire Hathaway, Roche and RTX headline Zacks??? latest stock reports, with growth drivers, catalysts and key risks in focus.
Top Stock Reports for Berkshire Hathaway, Roche & RTX
Berkshire Hathaway, Roche and RTX headline today's research, with earnings drivers, growth catalysts and risks shaping their outlooks.
Jazz Sparks On Its New Plan To Take On Roche; Hint: It's In Cancer
Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer.
Roche and Eli Lilly's pTau217 Blood Test Approved by FDA
Roche and Eli Lilly's pTau217 Blood Test Approved by FDA
RHHBY Looks 39.9% Overvalued on GF Value⢠Amid Solid Dividend Fundamentals
RHHBY Looks 39.9% Overvalued on GF Value⢠Amid Solid Dividend Fundamentals
RHHBY Looks 41.7% Overvalued on GF Value⢠Amid Solid Dividend Profile
RHHBY Looks 41.7% Overvalued on GF Value⢠Amid Solid Dividend Profile
Roche, Eli Lilly’s Alzheimer’s blood test gets U.S. FDA clearance
The U.S. Food and Drug Administration (FDA) has cleared Roche and partner Eli Lilly’s blood test to help identify signs of Alzheimer’s disease in people aged 55 and older with cognitive decline.
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55, Roche said on Monday m...
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.